Long-term survivors of LSelhi Tregs have sublethal GVHD
T effectors/LSelhi Tregs* . | GVHD scores . | Average ± SD . |
|---|---|---|
| Liver | ||
| None | 0, 1, 0, 0, 0 | 0.2 ± 0.45 |
| 1:1 | 1, 2, 1, 2.5, 1.5 | 1.6 ± 0.65† |
| 1:3 | 0.5, 0.5, 1.5, 1, 1 | 0.9 ± 0.42† |
| Lung | ||
| None | 1, 1, 1, 0, 0 | 0.6 ± 0.55 |
| 1:1 | 1, 1.5, 2, 3, 2 | 1.9 ± 0.74† |
| 1:3 | 2, 0.5, 2.5, 3.5, 3 | 2.3 ± 1.15† |
| Colon | ||
| None | 1, 1, 1, 0.5, 0.5 | 0.8 ± 0.27 |
| 1:1 | 1.5, 2, 1, 1.5, 1.5 | 1.5 ± 0.35† |
| 1:3 | 2, 2, 2, 2.5, 2 | 2.1 ± 0.22† |
| Skin | ||
| None | 0, 0, 0, 0, 0 | 0.0 ± 0.0 |
| 1:1 | 0.5, 0.5, 0.5, 0.5, 1 | 0.6 ± 0.22† |
| 1:3 | 0.5, 0.5, 0.5, 0.5, 0.5 | 0.5 ± 0.0† |
| Spleen | ||
| None | 0, 0, 0, 0.5, 0 | 0.1 ± 0.22 |
| 1:1 | 1.5, 2, 1, 2, 3 | 1.9 ± 0.74† |
| 1:3 | 1.5, 2.5, 3, 1, 2 | 2.0 ± 0.79† |
T effectors/LSelhi Tregs* . | GVHD scores . | Average ± SD . |
|---|---|---|
| Liver | ||
| None | 0, 1, 0, 0, 0 | 0.2 ± 0.45 |
| 1:1 | 1, 2, 1, 2.5, 1.5 | 1.6 ± 0.65† |
| 1:3 | 0.5, 0.5, 1.5, 1, 1 | 0.9 ± 0.42† |
| Lung | ||
| None | 1, 1, 1, 0, 0 | 0.6 ± 0.55 |
| 1:1 | 1, 1.5, 2, 3, 2 | 1.9 ± 0.74† |
| 1:3 | 2, 0.5, 2.5, 3.5, 3 | 2.3 ± 1.15† |
| Colon | ||
| None | 1, 1, 1, 0.5, 0.5 | 0.8 ± 0.27 |
| 1:1 | 1.5, 2, 1, 1.5, 1.5 | 1.5 ± 0.35† |
| 1:3 | 2, 2, 2, 2.5, 2 | 2.1 ± 0.22† |
| Skin | ||
| None | 0, 0, 0, 0, 0 | 0.0 ± 0.0 |
| 1:1 | 0.5, 0.5, 0.5, 0.5, 1 | 0.6 ± 0.22† |
| 1:3 | 0.5, 0.5, 0.5, 0.5, 0.5 | 0.5 ± 0.0† |
| Spleen | ||
| None | 0, 0, 0, 0.5, 0 | 0.1 ± 0.22 |
| 1:1 | 1.5, 2, 1, 2, 3 | 1.9 ± 0.74† |
| 1:3 | 1.5, 2.5, 3, 1, 2 | 2.0 ± 0.79† |
Survivors (n - 5/group) from Figure 1A were electively killed 7 months after transplantation and indicated GVHD target tissues were harvested, sectioned, and stained with hematoxylin and eosin and scored for GVHD histopathology. Shown are individual and average scores of a maximum score of 4.0.
Indicates the ratio of effector T cells to LSelhi Tregs
P = .018 vs “None”